Clinical Trials Logo

Lymphoma, T-Cell, Peripheral clinical trials

View clinical trials related to Lymphoma, T-Cell, Peripheral.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 4

NCT ID: NCT04052659 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Start date: April 15, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-center Phase II clinical trial for patients with relapsed or refractory Peripheral T-cell lymphoma (PTCL). Immunotherapy with anti-PD-1 antibodies, such as sintilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chidamide and azacitidine may respectively stop the growth of tumor cells by blocking histone deacetylation and DNA methylation enzymes needed for cell growth. Giving chidamide and azacitidine with sintilimab these three drugs may work better than single drug or combination of two drugs in treating patients with relapsed or refractory peripheral T-cell lymphoma.

NCT ID: NCT03553537 Not yet recruiting - Clinical trials for Peripheral T-cell Lymphoma

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Start date: June 2018
Phase: Phase 3
Study type: Interventional

Primary objective of the study is to compare the efficacy and safety of decitabine plus CHOP (D-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL).

NCT ID: NCT03051581 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether 18F-FDG PET/CT-based prognostic model of PTCL can predict disease progression

NCT ID: NCT03051568 Not yet recruiting - Clinical trials for Lymphoma, T-Cell, Peripheral

Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.

NCT ID: NCT03023358 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

Start date: February 2017
Phase: Phase 3
Study type: Interventional

The prognosis for Peripheral T cell lymphomas (PTCL) remains poor in comparison to B cell NHL. This is largely due to lower response rates and less durable responses to standard combination chemotherapy regimens such as CHOP. Whether CDOP plus Chidamide can improve the prognosis for PTCL.

NCT ID: NCT03000738 Not yet recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.

NCT ID: NCT02856997 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma

Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Chidamide with ICE regimen in patients with relapsed/refractory Peripheral T Cell lymphoma.

NCT ID: NCT00299351 Not yet recruiting - Clinical trials for Peripheral T Cell Lymphoma (PTCL)

A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.

Start date: n/a
Phase: Phase 2
Study type: Interventional

To evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on prior Gloucester-sponsored depsipeptide clinical trials, and in the opinion of their physician/ investigator might benefit from continued treatment with depsipeptide